{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Galera Therapeutics, Inc. technically bullish or bearish?
As of March 18, 2025, Galera Therapeutics, Inc. is in a mildly bearish trend, with daily moving averages and monthly indicators signaling bearishness, despite some mildly bullish weekly MACD and RSI readings.
Who are in the management team of Galera Therapeutics, Inc.?
As of March 2022, the management team of Galera Therapeutics, Inc. includes Dr. Michael Powell (Independent Chairman), Dr. J. Mel Sorensen (President and CEO), Dr. Emmett Cunningham, and independent directors Mr. Lawrence Alleva, Mr. Kevin Lokay, and Ms. Linda West. They oversee the company's strategic direction and operations.
What does Galera Therapeutics, Inc. do?
Galera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing therapeutics to enhance cancer radiotherapy. It has a market cap of $2.12 million and reported a net profit loss of $2 million as of March 2025.
How big is Galera Therapeutics, Inc.?
As of Jun 18, Galera Therapeutics, Inc. has a market capitalization of 2.12 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -16.16 million for the latest four quarters ending in March 2025. As of December 2024, the company's shareholder's funds were -143.67 million, and total assets amounted to 10.10 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
